Amir T Fathi

17PUBLICATIONS
66CO-AUTHORS
Molecular medicineGene and molecular therapyMedical molecular engineering of nucleic acids and proteinsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jun 30, 2026
A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.

|May 12, 2026
Defining a role for venetoclax and hypomethylating agent therapy in younger adults with acute myeloid leukemia.

|Feb 27, 2025
Integrative cytogenetic and molecular studies unmask "chromosomal mimicry" in hematologic malignancies.

Melissa Zhao, Scott Ryall, Samuel J Brody

|Apr 19, 2024
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.

Courtney D DiNardo, Gail J Roboz, Justin M Watts

|Mar 20, 2024
Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials.

Pau Montesinos, Amir T Fathi, Stéphane de Botton

|Mar 19, 2024
A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia.

Mark Levis, Alexander Perl, Gary Schiller

Pageof 3

Frequent Collaborators

4 joint publications

Areej El-Jawahri

3 joint publications

Gail Roboz

3 joint publications

Courtney D DiNardo

3 joint publications

Mark Levis